III期临床试验-话题@MedSci - williamhill asia

#III期临床试验#

101篇内容 | 1312人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1588089, encodeId=17c6158808927, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=55, createdTime=2022-04-04, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588088, encodeId=9da515880881d, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=67, createdTime=2021-11-06, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588087, encodeId=2647158808e02, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, objectType=article, longId=219261, objectId=3c982192618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c982192618a, replyNumber=0, likeNumber=57, createdTime=2021-10-27, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c982192618a, moduleTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3c982192618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588086, encodeId=6c881588086f7, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=55, createdTime=2021-10-19, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588085, encodeId=0bd51588085de, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=76, createdTime=2021-10-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588084, encodeId=464c158808415, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, objectType=article, longId=218128, objectId=301e21812880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e21812880, replyNumber=0, likeNumber=75, createdTime=2021-10-06, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e21812880, moduleTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=301e21812880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588083, encodeId=2eb21588083ac, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, objectType=article, longId=217765, objectId=135021e76506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135021e76506, replyNumber=0, likeNumber=57, createdTime=2021-09-29, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135021e76506, moduleTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=135021e76506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588082, encodeId=72111588082c6, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=布美他尼用于自闭症III期临床试验失败, objectType=article, longId=217084, objectId=f94e21e084df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94e21e084df, replyNumber=0, likeNumber=68, createdTime=2021-09-16, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94e21e084df, moduleTitle=布美他尼用于自闭症III期临床试验失败, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f94e21e084df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588081, encodeId=91a2158808161, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, objectType=article, longId=210178, objectId=c5462101e853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5462101e853, replyNumber=0, likeNumber=69, createdTime=2021-04-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5462101e853, moduleTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c5462101e853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588080, encodeId=ba281588080f1, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, objectType=article, longId=209159, objectId=3dc92091590c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc92091590c, replyNumber=0, likeNumber=70, createdTime=2021-03-31, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc92091590c, moduleTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3dc92091590c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588079, encodeId=b46e15880e95b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, objectType=article, longId=209081, objectId=08c1209081f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08c1209081f4, replyNumber=0, likeNumber=60, createdTime=2021-03-29, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08c1209081f4, moduleTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=08c1209081f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588078, encodeId=7c7115880e8ef, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, objectType=article, longId=208907, objectId=e5a320890ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a320890ef2, replyNumber=0, likeNumber=50, createdTime=2021-03-25, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a320890ef2, moduleTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e5a320890ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, objectType=article, longId=208679, objectId=00752086e9b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00752086e9b6, replyNumber=0, likeNumber=68, createdTime=2021-03-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00752086e9b6, moduleTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=00752086e9b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588076, encodeId=1fee15880e62e, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, objectType=article, longId=208482, objectId=a52b208482ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52b208482ca, replyNumber=0, likeNumber=80, createdTime=2021-03-18, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52b208482ca, moduleTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a52b208482ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588075, encodeId=5b3315880e53d, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, objectType=article, longId=207999, objectId=50a420e99915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a420e99915, replyNumber=0, likeNumber=72, createdTime=2021-03-08, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a420e99915, moduleTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=50a420e99915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588074, encodeId=50db15880e45c, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, objectType=article, longId=207295, objectId=aa7320e295db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7320e295db, replyNumber=0, likeNumber=62, createdTime=2021-02-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7320e295db, moduleTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=aa7320e295db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588073, encodeId=024215880e310, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=67, createdTime=2021-02-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588072, encodeId=18c715880e22c, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, objectType=article, longId=206565, objectId=0ffe20656522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffe20656522, replyNumber=0, likeNumber=62, createdTime=2021-02-03, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffe20656522, moduleTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0ffe20656522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588071, encodeId=e33915880e11d, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, objectType=article, longId=205630, objectId=ad3c205630c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3c205630c9, replyNumber=0, likeNumber=49, createdTime=2021-01-13, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3c205630c9, moduleTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ad3c205630c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588070, encodeId=b69015880e0d9, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, objectType=article, longId=205036, objectId=8f5c20503649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5c20503649, replyNumber=0, likeNumber=76, createdTime=2021-01-01, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5c20503649, moduleTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8f5c20503649)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

III期临床试验

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-04-04

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2021-11-06

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展

2021-10-27

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2021-10-19

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2021-10-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药

2021-10-06

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验

2021-09-29

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

布美他尼用于自闭症III期临床试验失败

2021-09-16

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验

2021-04-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始

2021-03-31

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果

2021-03-29

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点

2021-03-25

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-03-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点

2021-03-18

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果

2021-03-08

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验

2021-02-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-02-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验

2021-02-03

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验

2021-01-13

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验

2021-01-01

科室
- - 订阅+
  - 更多科室
工具
服务